The patient reported no known drug allergies ... hydrochloride 50 mg orally four times daily and ranitidine hydrochloride 150 mg orally twice daily for 10 days, in addition to the prednisone ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

GSK has settled lawsuits in the US that alleged the drugmaker’s now-discontinued heartburn drug Zantac triggered cancer ...

GSK did not admit wrongdoing as part of the deal, saying in a statement that there was "no consistent or reliable evidence" that ranitidine, the drug's active ingredient, increased the risk of cancer.

GSK shares in London jumped 5% Thursday after the British drug giant said it has resolved most of the U.S. lawsuits it faced ...

GSK has agreed to pay up to $2.2 billion to resolve approximately 80,000 lawsuits brought by users of Zantac who claimed the heartburn drug caused their cancer. The agreement frees the British ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

ranitidine, turned into the potential carcinogen NDMA under certain conditions. The US Food and Drug Administration asked companies producing Zantac to remove all ranitidine-based drugs from the U ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product liability cases in the U.S. state courts. These cases account for 93% ...